Foodie Pundit

The Pill That Could Cancel Cholesterol

A new pill, enlicitide, promises to lower cholesterol by 60%. We explore how this breakthrough could upend the food industry, from restaurants to grocery stores

By Foodie Pundit Newsroom - Published - Updated - Section: Food Safety

healthy meal plate vegetables photograph for this story

Key points

  • A new oral pill called enlicitide has been shown to lower 'bad' LDL cholesterol by approximately 60%, potentially removing one of the main health risks associated with high-fat foods.
  • The widespread availability of such a drug could fundamentally change the food industry, reducing demand for 'low-fat' and 'low-cholesterol' products and reviving interest in fats for flavor.
  • This pharmaceutical breakthrough does not eliminate other diet-related health concerns like obesity, diabetes, or high blood pressure, meaning overall nutritional awareness remains important.
  • The long-term effects on heart attack and stroke rates are still being studied, and the initial cost and accessibility of the new drug will be critical factors in its societal impact.

'''An entirely new era in our relationship with food may be dawning, and it arrives not in the form of a revolutionary diet or a miracle superfood, but as a small, once-daily pill. The pharmaceutical name is enlicitide, but its impact could fundamentally scramble the decades-old calculus of eating, wellness, and risk. For generations, the specter of high cholesterol has haunted the American plate, turning celebratory steaks, buttery pastries, and creamy cheeses into objects of anxiety. Now, the first-ever oral PCSK9 inhibitor, approved by the U.S. Food and Drug Administration, promises to neutralize that threat with astonishing efficacy, raising profound questions about the future of food culture, restaurant economics, and the very meaning of "healthy eating".

For anyone who has ever glanced at a nutrition label, the term "cholesterol" is loaded. Specifically, low-density lipoprotein cholesterol, or LDL-C, the so-called "bad" cholesterol, has been the primary villain in the narrative of American heart health. Elevated LDL-C is a primary driver of atherosclerotic cardiovascular disease, the insidious process where plaque builds up in the arteries, leading to heart attacks, strokes, and other serious vascular conditions. The public health messaging has been consistent and clear: manage your diet to manage your cholesterol.

This medical reality has had an undeniable and massive impact on the food industry. It fueled the rise of the low-fat craze of the 80s and 90s, filling supermarket shelves with bland, unsatisfying, and often sugar-laden products. It created a premium market for anything labeled "heart healthy".

It forced restaurant chains to add lighter fare to their menus and chefs to rethink their reliance on butter and cream. Entire CPG empires were built on the promise of lowering cholesterol, from fortified cereals to specific types of cooking oil.

The frontline defense against high cholesterol has long been a class of drugs called statins. Since their introduction, they have become one of the most widely prescribed medications in the world. When statins are not enough, doctors often turn to other treatments, including a powerful class of injectable drugs targeting something called PCSK9.

These injectable therapies work wonders, but their adoption has been hampered by a simple, human problem: people do not like giving themselves shots. The inconvenience, needle-phobia, high costs, and issues with accessibility have kept these potent treatments from reaching their full potential.

This is the world into which enlicitide enters. According to a pivotal paper published in the journal "Drug Discoveries & Therapeutics", this new drug represents a monumental shift. It is a macrocyclic peptide that performs the same function as its injectable counterparts but in a simple, easy-to-swallow pill.

It works by blocking the interaction between a protein, PCSK9, and LDL receptors in the liver. By doing so, it allows the liver to clear much more "bad" cholesterol from the bloodstream, effectively preventing it from building up in the arteries.

The clinical trial results are, to put it mildly, staggering. Phase III trials, known by the acronyms CORALreef Lipids and CORALreef HeFH, demonstrated that a once-daily dose of enlicitide slashed LDL-C levels by approximately 60 percent. This is not a marginal improvement; it is a seismic reduction.

Furthermore, the effect was sustained for up to a year, and the rates of adverse events were comparable to a placebo, suggesting a strong safety profile in the medium term. For the millions of Americans struggling to control their cholesterol through diet, exercise, and statins alone, this is a game-changer.

So, what happens when a pill can effectively "cancel" the primary negative consequence of eating rich, high-fat foods? The implications for our food system are vast and fascinating. The psychological burden of dietary restriction could, for a large segment of the population, simply evaporate.

The forbidden allure of a buttery croissant, a marbled ribeye, or a triple-cream brie would no longer be a negotiation between pleasure and peril. It would just be pleasure.

This shift could trigger a renaissance for fats in the culinary world. For decades, chefs have been challenged to deliver flavor while being mindful of the health perceptions of their diners. A world with widely available, highly effective oral cholesterol management could untether them from these constraints.

Imagine restaurant menus where butter, animal fats, and rich dairy are no longer seen as liabilities but celebrated as the unparalleled flavor-delivery vehicles they are. We could see a return to classical French techniques, a resurgence of traditional butchery that prizes marbling, and a new wave of dairy-centric desserts that do not shy away from their own decadence.

The economics of the restaurant industry would transform in tandem. The demand for "heart healthy" menu options could plummet, forcing a strategic pivot for chains and fine-dining establishments alike. The premium price point often attached to "healthier" dishes, which can sometimes be more expensive to source and prepare, might collapse.

Instead, the focus of value and quality would shift squarely back to sourcing, technique, and the pure, unadulterated flavor of the ingredients. A perfectly cooked steak would not need a "health halo" to justify its price; its quality would be its own justification.

This paradigm shift extends directly to the grocery store, the battleground where CPG giants have fought for consumer loyalty for a century. The "low-cholesterol" and "low-fat" labels that have been prime real estate on packaging for a generation could become obsolete, almost quaint. The market for foods engineered to lower cholesterol, from specialized margarines to fiber-fortified orange juice, could shrink dramatically.

Instead, consumer focus could pivot to other attributes: organic, non-GMO, sustainably sourced, ethically raised, or intensely flavorful. A shopper, no longer worried about the cholesterol impact of their choices, might be more willing to spend a premium on eggs from pasture-raised hens, not because they are "healthier" from a cholesterol standpoint, but because they taste better and align with their values on animal welfare. The marketing language of food would need a complete overhaul. "Rich and Creamy" could once again become a selling point, not a warning.

Sources and methodology

Reported from primary records. Open any source to verify a claim.

All sources Foodie Pundit reports from

More from the Foodie Pundit Newsroom

Permalink